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Abstract
Background: Alcohol is the leading psychoactive substance consumed in France, with about 15 million regular
consumers. The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more
than 14 units of alcohol a week for men and 7 units for women. The specific complication of alcoholism is the
alcohol withdrawal syndrome. Its incidence reaches up to 30 % and its main complications are delirium tremens,
restlessness, extended hospital stay, higher morbidity, and psychiatric and cognitive impairment. Without
appropriate treatment, delirium tremens can lead to death in up to 50 % of patients.
Methods/design: This prospective, double-blind, randomised controlled study versus placebo will be conducted in
twelve French intensive care units (ICU). Patients with an alcohol intake level higher than the NIAAA threshold, who are
under mechanical ventilation, will be included. The primary objective is to determine whether baclofen is more
efficient than placebo in preventing restlessness-related side effects in the ICU. Secondary outcomes include
mechanical ventilation duration, length of ICU stay, and cumulative doses of sedatives and painkillers received within
28 days of ICU admission. Restlessness-related side effects in the ICU are defined as unplanned extubation, medical
disposal removal (such as urinary catheter, venous or arterial line or surgical drain), falling out of bed, ICU
runaway (leaving ICU without physician's approval), immobilisation device removal, self-aggression or aggression
towards medical staff. Daily doses of baclofen/placebo will be guided by daily creatinine clearance assessment.
Discussion: Restlessness in alcoholic patients is a life-threatening issue in ICUs. BACLOREA is a randomised study
assessing the capacity of baclofen to prevent agitation in mechanically ventilated patients. Enrolment of 314 patients
will begin in June 2016 and is expected to end in October 2018.
Trial registration: ClinicalTrials.gov Identifier: NCT02723383, registered on 3 March 2016.
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Background
Alcohol is the leading psychoactive substance consumed
in France with about 15 million regular consumers. The
ESEMED4 study in 2001 [1] registered psychiatric disor-
ders in about 10 % of men and 2.5 % of women with
abusive alcohol intake. In 2013, alcohol was responsible
for one death every 12 min in France [2]. In general
hospitals, 20 to 35 % of men and 10 % of women suffer
from chronic alcoholism [3]. In an intensive care unit
(ICU), 28 % of admissions are related to abusive alcohol
intake [4]. The National institute on Alcohol Abuse and
Alcoholism (NIAAA) considers alcohol abuse to be
more than 14 units of alcohol a week for men and 7
units for women.
ICU admission is an independent risk factor for delirium
[5–7], pain-related health care issues, sleeping problems
and neurological dysfunction [8–10]. The specific compli-
cation of alcoholism is alcohol withdrawal syndrome. Its
incidence reaches up to 30 % [11] and its main complica-
tions are delirium tremens (DTs), restlessness, extended
hospital stay, higher morbidity, and psychiatric and cogni-
tive impairment [12–14]. Without appropriate treatment,
DTs can lead to death in 50 % of patients [15]. Alcohol
abuse leads to specific neurological dysfunction charac-
terised by a fall in neuronal density [16] and consequently a
higher risk of convulsion, confusion and restlessness [17].
Moreover, alcoholism also worsens vital prognosis [18, 19]
and increases the morbidity and mortality of surgical
patients [11, 20].
Alcohol withdrawal syndrome and delirium are com-
monly encountered in ICUs but standard treatment fails
to reduce restlessness and related complications. Agitation
related to DTs can lead to unplanned extubation and
medical disposal removal and requires deep sedation,
increasing the time on the ventilator. The beneficial effects
of baclofen in preventing such a condition have never
been reported in ICUs for at-risk drinkers.
Baclofen has been commercialised since 1974 and its
target is the type-B γ-aminobutyric acid (GABA)
receptor. In at-risk patients, this drug can reduce alcohol
craving. Randomised studies have reported its efficiency
in reducing both alcohol withdrawal syndrome [21, 22]
and alcohol intake [23, 24] with conclusive safety data.
Doses of up to 400 mg a day are commonly used, with
very few side effects, in outpatients with working lives.
Sixty to seventy percent of baclofen-treated patients
reached total abstinence with a mean daily dose of
147 mg [25]. These data, taken altogether, have led the
French medicinal and health products safety agency
(ANSM) to advocate new randomised controlled trials
to assess both the safety and efficiency of high doses.
Our objective is to take advantage of sedation and
mechanical ventilation to allow clinicians to deliver high
doses of baclofen without neuropsychiatric side effects
for quick and marked effects, in an attempt to control
restlessness, craving and related morbidity in ICU.
Methods/design
Design
BACLOREA is a prospective, multicentre, double-blind,
randomised controlled study versus placebo, performed in
at-risk drinkers according to NIAAA criteria. We will as-
sess the superiority of baclofen compared to placebo in
preventing restlessness-related complications. The ran-
domisation sequence will be computer-generated and
stratified at the 11 participating centres. This study follows
the international recommendations for interventional tri-
als (see the SPIRIT checklist in Additional file 1).
Hypothesis
Early administration of baclofen to at-risk drinkers may
reduce restlessness and its related complications when
sedation is interrupted. We hypothesise that the admin-
istration of baclofen can reduce the incidence of patients
who have at least one complication of agitation, includ-
ing: unplanned extubation, medical disposal removal,
falling out of bed, ICU runaway, immobilisation device
removal, and self-aggression or aggression toward med-
ical staff from 42 to 27 %.
Trial intervention
After randomisation, the patients will receive double-
blind baclofen or placebo. Daily doses will be adapted to
daily modification of the diet in renal disease (MDRD)
creatinine clearance from 150 to 50 mg (see Table 1).
On the day of randomisation, the patient will receive the
full daily dose in a one-shot administration. Then daily
doses will be divided into three intakes on the following
days. During the mechanical ventilation period, the
treatment/placebo will be administered via the nasogas-
tric feeding tube. After extubation, the treatment will be
administered either via the nasogastric tube or the oral
route. The doses were determined after a preliminary
pilot study and previous trial analysis regarding effi-
ciency and safety data [25].
The treatment will be tapered over a 7-day period
after extubation or tracheotomy, or after the 15th day
of treatment if the patient is still under mechanical
ventilation. Treatment will be interrupted as described
in Table 2.
Clinical and biological safety data will be collected
throughout the treatment period and the following
10 days, including blood count and liver function tests
(see Additional file 2: SPIRIT Figure 3).
Concomitant medication/treatment
All other interventions will be performed at the discre-
tion of the attending physicians. Participating ICUs will
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monitor sedation and pain in ventilated patients using
specific scales according to international guidelines [26].
Population
At ICU admission, patients with a mechanical ventila-
tion (MV) duration expected to be equal to or longer
than 24 h may be included.
For patients with tracheal intubation at ICU admission:
 If intubation was performed less than 48 h before
admission, inclusion can be performed within 24 h
after admission
 If intubation was performed 48 h or more before
admission, inclusion cannot be performed
For patients without tracheal intubation at ICU
admission:
 If intubation was performed within the first 48 h
after admission, inclusion can be performed in the
first 24 h after intubation
 If intubation was performed at or after 48 h,
inclusion cannot be performed
All patients, whatever the severity of organ failure,
would be eligible for screening inclusion.
Inclusion criteria
Adults aged from 18 to 70 years under mechanical ventila-
tion for 1 day or more with an estimated alcohol intake of:
 14 units of alcohol per week during the month
before hospitalisation for men aged 18 to 64
 7 units of alcohol per week during the month before
hospitalisation for women or men older than 65
Exclusion criteria
Patients fulfilling one or more of the following criteria
will not be included:
 Baclofen administration before ICU admission
(personal treatment or single administration)
 Pregnancy
 Porphyria
 Burn injuries on ICU admission
 Personal treatment including gamma-hydroxybutyric
acid (Alcover/Xyrem)
Table 1 Doses of baclofen or placebo adjusted on daily assessment of the patient’s creatinine clearance
MDRD D1 Loading dose D2 and following days until extubation/tracheotomy at D15
Cl ≥90 150 mg 50-50-50
Cl 89–60 100 mg 30-20-50
Cl 30–59 70 mg 20-20-30
Cl <30 or continuous HD 50 mg 20-10-20
IHD 50 mg 50 mg before each session
Cl <15 without HD/IHD 50 mg No administration
Cl renal clearance, D day, HD haemodialysis, IHD intermittent haemodialysis, MDRD modification of the diet in renal disease
Table 2 Gradual interruption of baclofen or placebo after extubation or tracheotomy or on the 15th day of treatment
Dose administered on the day
of extubation/tracheotomy/15th day
150 mg 100 mg 70 mg 50 mg IHD 50 mg
Day +1 100 mg (20-30-50) 70 mg (20-20-30) 50 mg (10-20-20) 30 mg (10-10-10) 30 mg before dialysis
(no administration if the
patient is not dialysed)
Day +2 70 mg (20-20-30) 50 mg (10-20-20) 30 mg (10-10-10) 20 mg (10-0-10) 30 mg before dialysis
(no administration if the
patient is not dialysed)
Day +3 50 mg (10-20-20) 30 mg (10-10-10) 20 mg (10-0-10) 10 mg (10-0-0) 10 mg before dialysis
(no administration if the
patient is not dialysed)
Day +4 30 mg (10-10-10) 20 mg (10-0-10) 10 mg (10-0-0) Stop Stop
Day +5 20 mg (10-0-10) 10 mg (10-0-0) Stop
Day +6 10 mg (10-0-) Stop
Day +7 Stop
IHD intermittent haemodialysis
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 Recent stroke or subarachnoid haemorrhage or head
trauma with radiological evidence
 Paraplegia or tetraplegia
 Cardiac arrest with resuscitation manoeuvres before
or after ICU admission
 Contraindication to enteral drug administration
 Lack of social protection
 Hypersensitivity to baclofen
 Coeliac disease
 Refractory epilepsy
 Dementia, schizophrenia, bipolar disorder or severe
depression
 Parkinson’s disease
 Health care limitation owing to a poor prognosis
 Tracheotomy on ICU admission
Randomisation and blinding
The clinicians will perform screening, enrolment and
randomisation. Randomisation is centralised, web-based
and accessible 24 h a day according to the allocation list
on https://www.dirc-hugo-online.org/csonline/. Random-
isation will be stratified at the centres using a fixed block
size of 1:1 and a randomisation number will be allocated
to each patient. Baclofen and placebo will be prepared and
‘blinded’ at Nantes University Hospital pharmacy. The
independent trial statistician, patients, clinicians and
nurses will be blinded for the allocation of treatment.
Primary outcome measure
Composite score: occurrence (yes or no) of agitation-
related adverse events during treatment/placebo admin-
istration with at least one sign out of the following:
 Unplanned extubation
 Medical disposal removal
 Falling out of bed
 ICU runaway
 Immobilisation device removal
 Self-aggression or aggression towards medical staff
Secondary outcome measure
 Composite score: occurrence (yes or no) of
agitation-related adverse events during treatment/
placebo administration or 28-day mortality
 Adverse event (yes or no) related to agitation within
28 days of ICU admission
 Number of adverse events related to agitation
occurring during ICU hospitalisation within 28 days
of ICU admission
 Restlessness requiring rapid intravenous or
intramuscular administration of hypnotic or
neuroleptic drugs within 28 days of ICU
admission
 Extubation failure defined as reintubation within the
next 48 h
 Tracheotomy for failure of mechanical ventilation
weaning
 Infections acquired in the ICU: urinary infection,
pneumonia, catheter infection or bacteraemia
 Total doses of sedatives and painkillers received in
the ICU within 28 days of ICU admission
 Riker Sedation Agitation Scale (SAS) in the ICU
within 28 days of ICU admission
 Daily Clinical Institute Withdrawal Assessment of
Alcohol Scale, revised (CIWA-Ar) alcohol withdrawal
score during the week following extubation
 Duration of mechanical ventilation
 Ventilation-free days (VFD) at day 28
 Length of ICU stay
 Length of total hospitalisation
 Death in ICU, at days 28 and 90
 Death during hospital stay
Participant withdrawal
Patients will be excluded from the trial if they or their
next-of-kin withdraw their consent. As a result, the
investigator will immediately interrupt treatment
administration.
If the patient does not object to information on the
primary outcome measure being obtained, the data will
be collected and analysed. The data will be fully erased if
the patient refuses this permission.
Protocol suspension and severe adverse reactions
The treatment could be discontinued:
 Temporarily if:
○ Renal clearance falls below 15 ml/min without
haemodialysis support
○ Liver tests (amino-transferase enzymes) are
more than 20 times the normal
○ Heart rate falls below 50 BPM with
haemodynamic consequences
 Definitively if:
○ Allergic symptoms appear
○ Heart rate falls below 35 BPM whatever the
haemodynamic profile
○ Non-reactive uni/bilateral mydriasis develops
○ Patient has a seizure in the ICU
○ Patient has a stroke in the ICU with computed
tomodensitometry (CT) scan confirmation
○ Eyes not open 72 h after total sedation is
interrupted
Statistics
We hypothesised that baclofen administration can re-
duce the incidence of patients with at least one
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complication of agitation, using a two-sided test with an
α of 5 % and 80 % power, from 42 to 27 %. This hypothesis
in the placebo group is based on personal data. As a result,
314 patients are needed. Our study will include patients
whatever their severity. Some patients may die before sed-
ation interruption thus altering the power of the study.
We therefore plan an interim analysis (after 50 % of inclu-
sions), to adjust the sample size to maintain the statistical
power. Friede and Kieser’s method [27, 28] allows both
the initial hypothesis and the type-1 error planned a priori
to be maintained. The analysis will be stratified at the par-
ticipating centres. Statistical analysis will take place on an
intention-to-treat principle. For the primary outcome, a lo-
gistic regression model will be applied to compare the pro-
portion of agitation between the two treatment arms. Two
sensitivity analyses will be performed and will consider
dead patients to be without agitation, or as patients with or
without agitation. A per-protocol analysis will also be per-
formed to exclude patients with any of the exclusion cri-
teria or without the inclusion criteria, or patients with
incomplete treatment administration.
For the secondary outcomes, a Poisson regression
model will be applied to compare the number of adverse
events related to agitation, between the two treatment
arms. Both length of ICU stay and mechanical ventila-
tion will be compared with a log-rank test. Logistic re-
gression will be used to compare binary qualitative
secondary endpoints.
Normally distributed variables will be expressed as
mean and standard deviation; nonnormally distributed
variables will be expressed as median and interquartile
range. Categorical variables will be expressed as num-
bers and percentages.
Track record
Data will be recorded in the web-based electronic case
report form (eCRF) by trial site staff. Characteristics at
baseline will be gathered: age, site of inclusion, sex, weight,
height, medical history, reason for ICU admission, alcohol
consumption, kidney function, Simplified Gravity Index
(IGSII) and Sequential Organ Failure Assessment (SOFA)
scores on admission. During ICU hospitalisation we will
assess: cumulative doses of all sedative drugs, agitation
and alcohol withdrawal scores, agitation-related adverse
events, blood tests results regarding alcohol test on
admission, liver function tests and blood count during
treatment, acquired infection, length of ICU stay,
mechanical ventilation and whole hospitalisation. To
preserve confidentiality of participant’s personal infor-
mation, data will be key-coded using alphanumerical
numbers. To minimise missing data, primary and
secondary outcome will be notified daily. Patients will
be monitored until day 90 and a supplemental telephonic
contact will promote complete follow-up.
Monitoring
Monitoring will follow Good Clinical Practice principles
and will be performed by the independent promotion
department of Nantes University Hospital Research
Management Unit. A clinical research associate (CRA)
will visit each centre every 6 months to control the quality
of the recorded data. The CRA will be able to check the
case report forms and medical records. The following data
will be assessed:
 Written informed consent
 Flow chart filled in for included and
excluded patients
 Trial progress
 Primary and secondary outcome collection
 Treatment-related severe adverse events
 Stock management of the study treatment
Participating centres agree to accept the promoter’s
quality audits.
Trial status
Patients from 11 ICUs are expected to be included over
a 2-year inclusion period. We plan to include two pa-
tients per ICU per month.
2015: protocol approval by the Ethics Committee and
French national drug safety agency.
June 2016–2018: inclusions
Beginning of 2017: interim analysis
2018: closing of the database. We will submit our
manuscript during the second half of 2018.
Discussion
Restlessness in alcoholic patients is a life-threatening
issue in ICUs. Baclofen usefullness was already reported
to treat alcohol withdrawal syndrome, that's why its ac-
curacy in ICU had to be assessed by large multicentre
studies. Invasive Mechanical ventilation and continuous
tight monitoring will allowed to introduce relatively high
doses of Baclofen to reach fast effective plasma drug
concentration and ensure patient security. In parallel, re-
ducing agitation may avoid other hypnotic drugs admin-
istration and so reduce their side effects: Mechanical
ventilation duration and its complications, delirium and
neuro-psychiatric aftereffects.
Additional files
Additional file 1: SPIRIT checklist. (DOC 117 kb)
Additional file 2: Figure 3 Study schedule. Caption of Figure 3: ICU,
Intensive care unit; SAS, Riker Sedation Agitation Scale; CIWA-Ar, Clin-
ical Institute Withdrawal Assessment of Alcohol Scale, revised; NIAAA,
National Institute on Alcohol Abuse and Alcoholism. (DOCX 136 kb)
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Ethics approval and consent to participate
Patient screening will start after Ethics Committee and French regulation
agency approvals have been obtained. State of the art suggests the
potential benefits of baclofen administration to patients suffering from
alcoholism without relevant or life-threatening side effects. Furthermore, if
baclofen succeeds in preventing restlessness in the ICU, its use may become
widely generalised since agitation is a serious issue in ICUs. The Ethics Committee
(‘Comité de Protection des Personnes ouest II’ for Angers, France) approved this
study protocol in 2015 (N° CPP 2015/09). The French National Agency for
Medicines and Health Products Safety gave its approval on 3 March 2016.
Most of the patients assessed for enrolment will not be able to provide
written consent and so will be included after emergency or next-of-kin
written consent has been obtained. Clinicians will ensure information
and consent collection. Baclofen must be delivered early after admission
in order to reach an efficient plasma concentration as quickly as possible. Very
few patients will be enrolled after obtaining their self-written consent. As soon
as patients recover consciousness and have a compatible mental status, clinicians
will ask them for their informed written consent.
Publication plan
The trial is registered on www.Clinicaltrials.gov. Upon trial completion the
main manuscript will be submitted for publication.
Safety
After the clinicians’ electronic report, the Pharmacovigilance Unit of Nantes
University Hospital will assess and manage solicited or spontaneously
reported adverse events.
A Data and Safety Monitoring Board (DSMB) will be available for this study, and
will include a methodologist, an intensivist and a specialist in alcohol abuse.
Members must be independent and not employed by the study sponsor.
The Monitoring Committee is responsible for the following:
 Providing independent medical expertise when necessary
 Providing independent expertise concerning the occurrence of
complications
 Judging whether the trial needs to be stopped on grounds of safety
or efficacy after interim analysis
The Monitoring Committee can request the promoter to unblind treatment
allocation in case of a serious adverse event.
Baclofen plasma concentration will be blindly assessed in three centres and
analyses will be centralised by the pharmacology laboratory in Nantes
University Hospital. Results will be anonymously analysed by the DSMB.
Author details
1Departments of Anaesthesiology and Surgical Intensive Care, Hôtel-Dieu,
University Hospital of Nantes, 44093 Nantes, France. 2Biometry Platform,
Research Promotion Department, University Hospital of Nantes, 44093
Nantes, France. 3EA 4275 SPHERE Methods for Patient-centered Outcomes
and Health Research, Nantes University, 44035 Nantes, France.
Received: 19 April 2016 Accepted: 4 August 2016
References
1. Alonso J, Ferrer M, Romera B. The European Study of the Epidemiology of
Mental Disorders (ESEMeD/MHEDEA 2000) project: rationale and methods.
2002;11(2):55-67. doi:10.1002/mpr.123.
2. Guerin S, Laplanche A, Dunant A. Alcohol-attributable mortality in France.
2013;23(4):588–93. doi:10.1093/eurpub/ckt015.
3. Vourc'h G, Hatton F, Tiret L. Epidemiologic study of anesthesia
complications in France. Bull Acad Natl Med. 1983;167(8):939–45.
Vourc’h et al. Trials  (2016) 17:415 Page 6 of 7
4. Canarelli T, Cadet A, Palle C. Indicateurs de la morbidité et de la mortalité
liées à l'alcool en France. Bull Epidemiol Hebdo. 2006;n°34-35:252–5.
5. Sanders RD, Pandharipande PP, Davidson AJ, Ma D, Maze M. Anticipating
and managing postoperative delirium and cognitive decline in adults. BMJ.
2011;343:d4331.
6. Pandharipande P, Shintani A, Peterson J. Lorazepam is an independent risk
factor for transitioning to delirium in intensive care unit patients.
Anesthesiology. 2006;104(1):21–6.
7. Pisani MA, Murphy TE, Araujo KLB, Slattum P, Van Ness PH, Inouye SK.
Benzodiazepine and opioid use and the duration of intensive care unit
delirium in an older population. Crit Care Med. 2009;37(1):177–83. doi:10.
1097/CCM.0b013e318192fcf9.
8. Lavie P. Sleep disturbances in the wake of traumatic events. N Engl J Med.
2001;345(25):1825–32. doi:10.1056/NEJMra012893.
9. Liang C, Chen J, Gu W. Chronic alcoholism increases the induction dose of
propofol. Acta Anaesthesiol Scand. 2011;55(9):1113–7. doi:10.1111/j.1399-6576.
2011.02497.x.
10. Wolfson B, Freed B. Influence of alcohol on anesthetic requirements and
acute toxicity. Anesthesia Analg. 1980;59(11):826–30.
11. Spies CD, Nordmann A, Brummer G, et al. Intensive care unit stay is
prolonged in chronic alcoholic men following tumor resection of the upper
digestive tract. Acta Anaesthesiol Scand. 1996;40(6):649–56.
12. Levkoff SE, Evans DA, Liptzin B, et al. Delirium. The occurrence and
persistence of symptoms among elderly hospitalized patients. Arch Intern
Med. 1992;152(2):334–40.
13. Francis J, Martin D, Kapoor WN. A prospective study of delirium in
hospitalized elderly. JAMA. 1990;263(8):1097–101.
14. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality
in mechanically ventilated patients in the intensive care unit. JAMA.
2004;291(14):1753–62. doi:10.1001/jama.291.14.1753.
15. Griffin RE, Gross GA, Teitelbaum HS. Delirium tremens: a review. J Am
Osteopath Assoc. 1993;93(9):924–929–32–935.
16. Kril JJ, Halliday GM. Brain shrinkage in alcoholics: a decade on and what
have we learned? Prog Neurobiol. 1999;58(4):381–7.
17. Neiman J. Alcohol as a risk factor for brain damage: neurologic aspects.
Alcohol Clin Exp Res. 1998;22(7 Suppl):346S–51.
18. Gacouin A, Tadie JM, Sauvadet E. At-risk drinking is independently
associated with ICU and one-year mortality in critically ill nontrauma
patients*. Crit Care Med. 2014;42(4):860–7. doi:10.1097/CCM.
0000000000000041.
19. Clark BJ, Williams A, Feemster LMC, et al. Alcohol screening scores and
90-day outcomes in patients with acute lung injury. Crit Care Med.
2013;41(6):1518–25. doi:10.1097/CCM.0b013e318287f1bb.
20. Tønnesen H, Petersen KR, Højgaard L, et al. Postoperative morbidity among
symptom-free alcohol misusers. Lancet. 1992;340(8815):334–7.
21. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of
alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med.
2006;119(3):276.e13–e18. doi:10.1016/j.amjmed.2005.08.042.
22. Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol
withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled
trial. J Hosp Med. 2011;6(8):469–74. doi:10.1002/jhm.928.
23. Addolorato G, Leggio L, Ferrulli A, Cardone S. Effectiveness and safety of
baclofen for maintenance of alcohol abstinence in alcohol-dependent
patients with liver cirrhosis: randomised, double-blind controlled study. The
Lancet. 2007;370(9603):1915–1922. doi: 10.1016/S0140-6736(07)61814-5.
24. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al.
Dose–response effect of baclofen in reducing daily alcohol intake in alcohol
dependence: secondary analysis of a randomized, double-blind, placebo-
controlled trial. Alcohol and Alcoholism. 2011;46(3):312–317. doi:10.1093/
alcalc/agr017.
25. Rigal L, Alexandre-Dubroeucq C, de Beaurepaire R. Abstinence and ‘low-risk’
consumption 1 year after the initiation of high-dose baclofen: a
retrospective study among ‘high-risk’ drinkers. Alcohol Alcohol. 2012;47(4):
439–42. doi:10.1093/alcalc/ags028.
26. Riker RR, Fraser GL. The new practice guidelines for pain, agitation, and
delirium. Am J Crit Care. 2013;22(2):153–7. doi:10.4037/ajcc2013480.
27. Friede T, Kieser M. Sample size recalculation for binary data in internal pilot
study designs. Pharm Stat. 2004;3(4):269–79. doi:10.1002/pst.140.
28. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a
review. Biom J. 2006;48(4):537–55.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Vourc’h et al. Trials  (2016) 17:415 Page 7 of 7
